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 IMMUNE RESPONSE TO BK VIRUS REACTIVATION IN RENAL 
TRANSPLANT RECIPIENTS  
 
AMAARA BABWAH 
 
ABSTRACT 
 
  BK virus, a virus of the polyomaviridae family, is a latent infection in up to 
70% of the general population. However, it has been an emerging cause of renal 
allograft dysfunction in kidney transplant recipients. Existing research has 
elucidated the risk factors that may precipitate BK viremia and BK Virus 
Associated Nephropathy. Research into the humoral and adaptive immune 
response to BK reactivation is still ongoing. 
 This thesis is part of a larger study that aims to further elucidate the 
various aspects of the cellular response to BK reactivation. It focuses on the 
methods of quantitation of BK virus pre-transplant, 1 month, 3 months, 6 months 
and 12 months post-transplant. Laboratory qPCR and clinical PCR assays were 
conducted and analyzed. Various aspects of the cellular and humoral response 
were also examined and analyzed. As there exists no standard protocol for BK 
surveillance in kidney transplant recipients, analysis of these data will 
undoubtedly pave the way for future research in this field.  
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 It was concluded that BKV levels in plasma and urine should be more 
stringently monitored and the required assays perfected for a higher degree of 
sensitivity.  
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INTRODUCTION 
 
 Organ transplant patients are particularly susceptible to viral infection. 
Pharmacologic immunosuppression tempers the recipient’s immune response, 
thereby preventing or reducing the risk of graft dysfunction or rejection. Kidney 
transplant patients are uniquely vulnerable to polyomavirus-associated 
nephropathy (PVAN), an organ pathology of the BK virus pathogen. Such 
immunosuppression, while it prevents allograft rejection, promotes the 
reactivation of the polyomavirus. BKV infection is clinically significant as it may 
lead to ureteric stenosis, hemorrhagic cystitis, transient renal dysfunction and BK 
Associated Nephropathy (BKVAN). There has been an increasing prevalence of 
BKVAN and is one of the leading causes of renal allograft loss in the first two 
years after transplantation (Hirsch, 2005).  BKVAN presents in 1-5% of renal 
transplant recipients and results in allograft failure in approximately 50% of cases 
(Hirsch et al, 2002). 
 In order to successfully predict, diagnose and treat BKVAN in KTR 
(Kidney Transplant Recipients), its pathogenesis was must be first understood. 
The immune response to BKV infection in renal allograft recipients is 
multifaceted. BKVAN may develop due to a combination of suppressed 
surveillance by recipient T lymphocytes, lack of recipient humoral immunity, the 
variability of the BK genetic material and alloimmune activation (Dall & Hariharan, 
2008).  
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 This thesis is a part of a much larger assessment of the immune response 
to BK infection post-transplant. It focuses on the methods of quantitation of BK 
virus pre-transplant, 1 month, 3 months, 6 months and 12 months post-
transplant. During the course of data collection, a large regional conference, 
NEBKCON (New England BK Consortium), on BK was organized and attended 
by 12 academic medical centers across New England. It was revealed that every 
center approached BK surveillance and treatment differently as there are no 
standardized protocols nationally or internationally.    
 
BK Polyomavirus 
BK virus (BKV) or Polyomavirus hominis type 1, named after the first 
diagnosed patient in 1971, belongs to the Polyomaviridae family. The virus itself 
consists of a circular double-stranded genome of approximately 5kb, surrounded 
by a non-enveloped icosahedral capsid (Hirsch, 2005). The entire genome of 
BKV, along with its replication origin, splice sites, early and late viral proteins was 
published in 1979 (Seif et al, 1979) (See Figure 1). The five gene products of 
interest in BK virus are the polypeptides large T antigen and small T antigen and 
the structural proteins VP1, VP2 and VP3. VP1 is the main capsid protein and 
exists as pentamers arranged in a T=7 icosahedral lattice (Nilsson et al, 2005). 
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Figure 1: Circular Map of the BKV Genome 
The map of BKV DNA is oriented with the single RI site at 0.0. The two coding 
regions are defined by the gene functions expressed primarily before (early) and 
after (late) viral DNA replication. Arrows extending from a region near the origin 
for viral DNA replication indicate the direction of transcription. The spliced early 
and late viral mRNAs are positioned outside the circular genome with intervening 
sequences indicated by dots. Protein coding regions are depicted by thick lines 
on each mRNA.  
Original image from Seif et al, 1979, Cell. 
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There are four classes (I-IV) of BKV genotypes, based on the variability of 
VP1. The classes of BKV genotypes are geographically distributed and it is 
postulated that it follows human migration patterns (Polz et al, 2013). The most 
prevalent class is type I. However, its significance of the different classes with 
respect to pathogenesis remains ambiguous (Polz et al, 2013). VP1 is also the 
capsid protein of relevance in this study. BK virus shares approximately 75% 
homology with another human polyomavirus, JC (Nilsson et al, 2005).  
Epidemiologically, more than 70% of the general adult population is 
seropositive for BKV (Hirsch, 2005). Although it has not been confirmed, it is 
postulated that the route of infection may be either respiratory or oral-fecal. It 
may even be transmitted sexually as BK virus has been found in prostate tissues 
and seminal fluids (Polz et al, 2013). BK Virus may also be transmissible trans-
placentally as BKV DNA has been detected in cord blood, fetal and placental 
tissues (Hirsch, 2003). Infection typically occurs during childhood, then enters an 
asymptomatic state of non-replicative infection, “latency,” in the renal tubular 
cells, uroepithelial cells and prostate tissue (Hirsch, 2005).  
BK polyomavirus, as its viral classification, “polyoma” suggests, has the 
capability to induce multiple tumors. It has also been hypothesized that its 
oncogenic nature presents as a model system for studying gene regulation in 
both lytically infected and transformed cells (Seif et al, 1979). 
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Figure 2. Images of healthy cortical tissue and cortical tissue exhibiting 
BKVAN. The upper image shows healthy tissue while the lower image shows BK 
nephropathy. Adapted from Drachenberg et al, 2004. 
 
BK Virus Reactivation Post-transplant  
Post-transplantation, pharmacologic immunosuppressive therapy, in the 
form of calcineurin inhibitors, mTOR inhibitors, corticosteroids, 
immunosuppressive monoclonal antibodies or antimetabolites, is employed so as 
to reduce the risk of renal allograft loss or dysfunction (Hirsch, 2002). However, it 
is this very intervention that triggers the reactivation of the BK virus. Thus, a 
paradox arises. Immunosuppression is necessary to prevent the host’s immune 
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system from attacking the allograft while simultaneously increasing the likelihood 
of BK reactivation and subsequently leading to BKVAN. As such, meticulous 
surveillance is required in order to maintain the balance between BK viremia and 
allograft rejection (Hirsch, 2002).  
 
Risk Factors for BK Virus Infection Post-transplantation  
It is widely accepted that the most significant risk factor for reactivation of 
the BK virus is over-immunosuppression (Sawinski & Goral, 2015). Other risk 
factors include male gender, older recipient age, prior rejection episodes, degree 
of HLA mismatching, prolonged cold ischemia time, BK serostatus, 
cytomegalovirus infection and ureteral stent placement (Sawinski & Goral, 2015).  
 
 
 
BK Virus Infection: Clinical Presentation, Diagnosis and Treatment of 
BKVAN 
BK virus infection first presents as viuria then progresses to viremia, then 
BKVAN (See Figure 2). Although BK viremia is typically detected by quantitative 
polymerase chain reaction (qPCR), the gold standard for establishing a diagnosis 
of BKVAN is a kidney biopsy. However, this method is highly invasive and allows 
little opportunity for therapeutic intervention, as observable pathological changes 
in the kidney occur very late in the progression BKVAN (Yoon et al, 2015). As 
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such, it is acknowledged that routine surveillance for BKV in kidney transplant 
recipients is far more helpful in predicting BKVAN and monitoring therapy 
(Limaye et al, 2001).  
 
 
Figure 3: Kaplan-Meier Estimates of BK Virus Replication, Viremia and 
Nephropathy in 78 Renal Transplant Recipients. Viral replication was defined 
by the presence of decoy cells in the urine. Viremia was defined by the detection 
of BKV DNA by PCR assay. BKVAN was diagnosed on the basis of histologic 
findings in allograft-biopsy specimens. Original image from Hirsch et al, 2002.  
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One study in particular, conducted at Kyungpook National University 
School of Medicine in Korea, investigated the clinical impact of BK virus 
surveillance on outcomes in 213 kidney transplant recipients. BK viral loads were 
monitored monthly for the first 6 months, then every 3 months for 1 year after 
transplantation. It was thus reported that the window for identifying BK viremia 
before the onset of BKVAN is 2 to 6 weeks, and as such, it was concluded that 
monthly plasma screening allows for timely therapeutic intervention.  
However, there remains no specific treatment for BKVAN. Reduction in 
immunosuppression is the main method of intervention employed in order to 
prevent the progression from BK viremia to BKVAN (Sawinski, Goral, 2015).  
According to a study conducted at the Medical College of Wisconsin, reduction in 
the calcineurin inhibitor dose resulted in stabilization of renal function in kidney 
transplant patients with BKVAN. However, it was found that this was not true for 
overall immunosuppression (Vasudev et al, 2015). The immunosuppressive 
medications used in this study included Prednisone, Azathioprine, Cyclosporine, 
Tacrolimus, Mycophenolate mofetil and Sirolimus. In their single center, 
retrospective study, the median diagnostic time was 11 months post renal 
transplant. Vasudev et al proffer that because BKVAN is a late complication of 
renal transplantation, loss of the renal allograft still occurred in 46% of transplant 
patients despite the reduction in immunosuppression.  
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In a study conducted at the University of Maryland Renal Transplant 
Program, it was found that there is no difference in the rate of acute allograft 
rejection among different immunosuppression protocols.  
 
Immune Response to BK Virus Infection 
An exhaustive review of the literature on the pathogenesis of BK infection 
after renal transplantation has yielded conflicting results. The immune responses 
to the five different BK virus proteins, large T antigen, small T antigen, VP1, VP2 
and VP3, have been the major approach to research into the immune response 
to BK infection. Most research has focused on the immune response to large T 
antigen (LT) and VP1 (Prosser & Hariharan, 2006). It was found that the 
response is primarily CD4+ mediated compared to CD8. However, research at 
the Institute of Medical Microbiology in Switzerland has found that both LT and 
VP1 gene products contain epitopes for both CD4+ and CD8+ cell recognition 
(Dall & Hariharan, 2008). Yet another study at the Division for Viral Pathogenesis 
showed that there were two epitopes within the VP1 capsid protein that are 
recognized by cytotoxic T lymphocytes (CTLs) (Chen et al, 2006).  
The role of BK serostatus of both the allograft donor and recipient has also 
been a significant subject of research. A 2005 study at the University of 
Washington found that patients who received renal allografts from a seropositive 
donor were more likely to develop BK viremia than those who received allografts 
from a seronegative donor (Bohl et al, 2005). Renal allograft recipients with 
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humoral immunity against BK virus may never clinically exhibit symptoms of BK 
viral infection, regardless of the circulating number of viral copies (Bohl et al 
2005). 
It has also been found that a higher degree of HLA mismatching correlates 
with a higher incidence of BKVAN in renal transplant recipients (Awadalla et al, 
2004). 
 
Other treatments for BK Viremia and BKVAN 
There are several other treatments for BK viremia and BKVAN. 
Intravenous Immunoglobulin (IVIG) contains the pooled IgG immunoglobulins 
from more than one thousand blood donors. Together with a reduction in 
immunosuppression, IVIG treatment has shown to be a successful treatment. 
However, the efficacy of IVIG as a sole treatment remains contentious (Dall & 
Hariharan, 2008). 
Antivirals such as Cidofovir and Leflunomide have been used in the past 
as treatments for BKVAN. However, the use of antivirals alone has not been 
unequivocally successful (Vasudev et al, 2015). 
Fluoroquinolones such as Ciprofloxacin in particular, inhibit synthesis of 
bacterial DNA but also have activity against the viral helicase TAg (large T 
antigen). However, it has not shown to be an effective treatment on its own (Polz 
et al, 2013). 
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Lastly, monoclonal antibodies such as Anti CD20 Rituximab, has shown 
promising results. In one study, kidney transplant patients treated with Rituximab 
showed no allograft loss compared with 46% allograft loss in the control group 
(Babel et al, 2007). 
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SPECIFIC AIMS AND OBJECTIVES 
 
 Many factors contribute to the probability of a kidney transplant recipient 
developing BKVAN in the first two years post-transplant. It is the objective of this 
thorough statistical analysis to identify the aspects of the transplant process and 
post-transplant surveillance that can be manipulated in order to minimize the risk 
of developing BKVAN after a kidney transplant.  
 The specific aims of the study are: 
1. To ascertain the relationship between immune response and post-
transplant degree of viremia and viuria. 
2. To improve or establish a standard protocol for BK virus surveillance in 
kidney transplant patients. 
3. To employ various methodologies and master a variety of assays and 
techniques in order to better observe the immune response to BKV 
reactivation. 
4. To examine the degree of BK viremia against the level of pharmacologic 
immunosuppressant. 
 
It is the intention of this analysis to discover more about the immunological 
progression of BK infection in kidney transplant recipients. With improved 
surveillance, it is hoped that the in the clinical setting, the incidence of BKVAN as 
well as allograft dysfunction and loss can be reduced. 
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METHODS 
 
This study was conducted at Beth Israel Deaconess Medical Center 
(BIDMC) and at Brigham and Women’s Hospital (BWH) and was approved by the 
IRBs (Internal Review Board) at both institutions. Patients were consecutively 
enrolled at the transplant centers of both hospitals from 2012 to 2015. For each 
patient, both plasma and urine samples were collected pre-transplant, then at 1 
month, 3 months, 6 months and 12 months post-transplant. Plasma and 
peripheral blood mononuclear cells (PBMC) were isolated and aliquots of PBMC, 
plasma and urine were stored at ─80°C.  Demographic and clinical information, 
including BKV urine and serum PCR screening values were collected from the 
medical record. 
 
DNA Extraction 
Using the QIAamp® MinElute® Virus Spin kit and protocol, the BK virus 
was extracted from each plasma and urine sample.  
First, each sample was treated with 25µg of the provided protease, lysis 
buffer and carrier RNA. The samples were then incubated at 56ºC while being 
shaken at 14000rpm. They were then treated with 250µg of 100% ethanol. The 
contents of each tube were then transferred to the MinElute® columns and 
centrifuged at 8000rpm. The columns were then subjected to consecutive 
washings with buffers AW1, AW2 and 100% ethanol. Finally, the columns were 
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eluted with 150µg of the provided elution buffer. The collected solution was then 
stored for further analysis by qPCR. 
 
Preparation for qPCR – Bacterial Transformation 
Bacterial transformation was performed using Agilent Technologies 
competent E. cells and a pUC18 control plasmid. First, the pUC18 DNA was 
diluted 1:10 with UltraPureTM DNase/RNase-Free Distilled Water. 1µL was then 
added to a tube of E. coli cells. After a 20-minute incubation on ice, 250µL of 
heated SOC medium was added and the mixture incubated at 37ºC for one hour 
in a shaker.  
LB-ampicillin agar plates were prepared using 5g NaCl, 5g Tryptone, 2.5g 
Yeast Extract, 7.5g agar and UltraPureTM water. The solution was autoclaved for 
20 minutes and allowed to cool to 55ºC. 0.5mL ampicillin was added to the 
cooling LB agar solution. Approximately 20mL of LB agar were poured into each 
petri dish. The plates, sealed in parafilm, were allowed to cool and solidify over 
night at 4ºC.  
The transformed bacteria (5µL) was then plated and spread on the LB-
ampicillin agar plates. The plates were incubated overnight at 37ºC. One single 
colony was then chosen, the cells lysed and centrifuged in order to yield 
homogenous bacterial plasmid. Two batches of BK plasmid were prepared using 
the Qiagen Midi Plus Plasmid High Yield Purification kit. The concentration of BK 
plasmid each batch was determined using a NanoDrop® spectrophotometer. 
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Calculations were then performed in order discern the concentration of BK 
plasmid in number of copies per unit volume. These calculations are shown in 
Table 4. 
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qPCR  of Plasma and Urine Samples 
A serial dilution was performed in order to create a standard curve. The 
dilutions were executed according to the calculations in Table 1.  
 
Table 1: Serial Dilution for BK Standard Curve for qPCR. 
 
Solution Volume of 
ddH2O /  𝝁𝑳 Volume of Plasmid Solution Final Concentration in 𝒄𝒐𝒑𝒊𝒆𝒔𝝁𝑳  
1 243 7.04  𝜇𝐿 of BKV Batch 2 1x109 
2 180 20  𝜇𝐿 of Solution 1 1x 108 
3 180 20  𝜇𝐿 of Solution 2 1x 107 
4 180 20  𝜇𝐿 of Solution 3 1x 106 
5 180 20  𝜇𝐿 of Solution 4 1x 105 
6 180 20  𝜇𝐿 of Solution 5 1x 104 
7 180 20  𝜇𝐿 of Solution 6 1x 103 
8 180 20  𝜇𝐿 of Solution 7 1x 102 
9 180 20  𝜇𝐿 of Solution 8 1x 101 
10 75 75  𝜇𝐿 of Solution 9 5x100 
 
The Invitrogen primers used in the qPCR reactions were BKVP1 2511 5’–
AGT GGA TGG GCA GCC TAT GTA-3’ and BKVP1 2586 5’–TCA TAT CTG 
GGT CCC CTG GA-3’ and were diluted according to Table. BKV Major Primer 
Probe Mix was made according to the dilutions and volumes in Table 2.  
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Table 2: Volumes of reagents used for preparation of Primer Probe Mix 
 
  BKV Major Primer Probe mix (10x) 
BKVP1 2511 (diluted 1:20) 80  𝜇𝐿 
BKVP1 2586 (diluted 1:20) 80  𝜇𝐿 
Probe 10  𝜇𝐿 
ddH2O 330  𝜇𝐿 
Total Volume 500  𝜇𝐿 
 
Master Mix was then made using the prepared Primer Probe Mix and 
Universal Taq Man in the ratios presented in Table 3.  
 
Table 3: Volumes of solutions used to prepare Master Mix for 18 reactions. 
 Volume per well / 𝜇𝐿 Total volume for 18 
reactions 
 
Taq Man (2x) 25 495 
Primer Probe Mix 5 99 
 
 
 
The 50µL reactions, 30µL Master Mix and 20µL DNA extracted from 
sample of plasma or urine, were plated in a sterile 96 well plate in a UV sterilized 
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PCR hood. Each sample was run in triplicate. The plate was then sealed with 
adhesive and centrifuged at 1400 rpm for 1 minute. The appropriate settings 
were configured on the Applied Biosystems qPCR machine and the plate was 
allowed to run for 40 amplification cycles. The 5’ end of the probe was labeled 
with a FAM dye and the 3’ end labeled with TAMRA dye.  
A positive result for any sample was confirmed only if two out of three or 
three out of three wells yielded detection for BKVP1. 
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RESULTS 
 
 
Plasma and urine samples were collected from 29 patients and stored at -
80ºC until DNA extraction was performed. In total, 121 plasma samples and 92 
urine samples were collected and stored. 
 
DNA Extraction 
The DNA extractions were performed without incident using the QIAamp® 
MinElute® Virus Spin kit. It was verified that DNA was indeed extracted using a 
NanoDrop® spectrophotometer. The machine calculated the concentration of 
DNA by measuring the Absorbance of nucleic acid material in 2uL of extract.  
 
Preparation for qPCR – Bacterial Transformation 
The bacteria was successfully transformed and colonies grown. The BKV 
concentration of each batch was calculated using the NanoDrop® 
spectrophotometer. The graphical representation of the absorbance spectra is 
shown in Figure 3.  
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   Table 4: Calculations yielding concentrations of BK plasmid after plasmid prep. 
 
  
 Concentration 
in 𝒏𝒈𝝁𝑳 Calculation using multiplier Concentration in 𝒄𝒐𝒑𝒊𝒆𝒔𝝁𝑳  
BKV 
Batch 
1 
282 282𝑛𝑔𝜇𝐿 × 9.588×10!"𝑐𝑜𝑝𝑖𝑒𝑠𝜇𝑔  
 
2.66×10!" 
BKV 
Batch 
2 
386.9 386.9𝑛𝑔𝜇𝐿 × 9.588×10!"𝑐𝑜𝑝𝑖𝑒𝑠𝜇𝑔  
 
3.55×10!" 
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Figure 4. Absorbance spectra and BKV plasmid concentration. 
 
qPCR Results 
The standard for qPCR was prepared via serial dilutions. The standard 
curve is shown in Figure 4 and Figure 5.  
	  22 
 
Figure 5.  Delta Rn vs Cycle showing standard curve for selected plasma 
samples. Graphical representation of well prepared standard as graph shows 
consistent dilutions with evenly spaced amplification lines at threshold.  
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Figure 6. Standard curve for selected plasma samples. This representation of 
the standard curve shows an efficiency of approximately 98% based on the 
slope.  
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Figure 7. Delta Rn vs Cycle showing positive detection of BKV in selected urine 
samples. Graphical representation of amplification of positive samples. The 
negative samples do not cross the threshold line as seen at 1x100. 
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 The results presented in Table 5 and Figures 7 and 8 represent the main 
data from the quantitation of BKV in the plasma and urine samples of the patients 
in this study.  
 
Table 5. Numbers of patients exhibiting viremia and viuria according to qPCR 
data. 
 
Number of Patients exhibiting 
viremia according to qPCR results. 
Number of Patients exhibiting viuria 
according to qPCR results. 
0 6 
 
 
 
 
 
 
 
 
 
 
Figure 8. Pie chart showing proportion of viremic patient according to qPCR 
results. 
 
 
 
0%	  
100%	  
Proportion of patients exhibiting 
viremia according to qPCR 
Patients	  with	  viremia	  Patients	  with	  no	  viremia	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Figure 9. Pie chart showing proportion of patients exhibiting viuria according to 
qPCR data. 
 
 
Clinically validated PCR assays were also performed pre-transplant, at one 
month, 3 months, 6 months and 12 months post-transplant. This is significant as 
the resulting data revealed discrepancies between the assays performed in the 
clinic and in the laboratory. Figure 9 illustrates this mismatch as represented by 
total numbers of patients exhibiting viuria and viremia. The inconsistencies were 
further examined at each time point as represented in Table 6 for viuria and 
Table 7 for viremia.  
  
21%	  
79%	  
Proportion of patients exhibiting 
viruria according to qPCR 
Patients	  with	  viuria	  Patients	  with	  no	  viruria	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Observed Discrepancies Between Lab and Clinical Data 
  
Figure 10. Bar graph quantifying the numbers of patients exhibiting viuria and 
viremia according to both laboratory and clinical PCR assays. It must be noted 
that the clinical assay detected both viuria and viremia at more time points for 
each patient than did the laboratory assay. 
 
 
Table 6. Comparison between clinical and laboratory data for viuria. This table 
provides the numbers of patients exhibiting viuria at the 5 time-points of interest 
in this study for each set of assays. 
 
 Number of patients 
exhibiting viuria 
according to clinical 
PCR data 
Number of patients 
exhibiting viuria 
according to laboratory 
PCR data 
Baseline / Pre-transplant 0 1 
1 month post transplant 3 0 
3 months post transplant 5 5 
6 months post transplant 6 3 
12 months post 
transplant 
2 0 
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Table 7. Comparison between clinical and laboratory data for viremia. This table 
provides the numbers of patients exhibiting viuria at the 5 time-points of interest 
in this study for each set of assays. 
 
 Number of patients 
exhibiting viremia 
according to clinical 
PCR data 
Number of patients 
exhibiting viremia 
according to laboratory 
PCR data 
Baseline / Pre-transplant 0 0 
1 month post transplant 0 0 
3 months post transplant 2 0 
6 months post transplant 2 0 
12 months post 
transplant 
0 0 
 
 
It must be noted that blood and urine specimens were not stringently collected at 
every single time-point for each patient for both clinical and laboratory analysis 
(See Table 8). In some cases, the laboratory and clinical samples were collected 
on different days (See Table 9). 
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Table 8 Tally of missing biological specimens. This table tallies the numbers of 
missing biological specimens. The number of missing clinical samples was 
undocumented. 
 Numbers of laboratory 
samples missing at 
each time-point 
Pre-transplant 5 
1 month post-transplant 4 
3 months post-transplant 7 
6 months post-transplant 14 
12 months post-transplant 14 
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Table 9.	  Positive results for Urine qPCR and dates of specimen collection.  
Laboratory Urine qPCR 
/ 𝒄𝒐𝒑𝒊𝒆𝒔𝒎𝑳  
Date collected by lab Date collected by clinic 
3.46x107 7/21/14 7/21/14 
2560 7/22/13 7/22/13 
20942 10/03/13 10/03/13 
1706 Date unrecorded 11/14/13 
34453 6/27/13 6/7/13 
4551 9/25/13 9/25/13 
893 1/16/14 1/15/14 
137.33 5/7/14 5/21/14 
482000 9/17/13 9/17/13 	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Figure 11.	  	  Serology data showing levels of Anti BKV IgG for viuric, viremic and 
BK negative patients at each time-point. Adapted from analysis performed by 
Dave DeWolffe MD.	  
 
 
 
Figure 12 Gender distribution of patients in study. 
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Figure 13. Bar graph showing the race distribution of the patients in the study.  
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Table 10. Population Charateristcs (Adapted from the work of Dave DeWolffe, 
MD). 
    BK Viremia  BK Negative  P Value  
Number of Patients  3  25    
Recipient Age (Years)  45.71 (± 
19.4)  
52.07 (± 
12.2)  
 P= 0.60  
Recipient Gender        
  Male  3  17    
  Female  0  8  P= 0.56  
Recipient Race        
  Caucasian  2  23    
  AA  1  1    
  Asian  0  1  P= 0.30  
Cause of Renal Disease        
  Diabetes  2  10    
  Primary GN  1  4    
  ADPKD  0  4    
  Obstruction/P
yelonephritis  
0  3    
  Other  0  4  P=  1.00  
On RRT at time of transplant        
  Yes  2  5    
  No  1  16  P=  0.19  
Induction Immune 
Suppression  
      
  rATG  2  20    
  Simulect  1  3  P= 0.41  
Prednisone Use        
  Yes  2  4    
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  No  1  21  P= 0.11  
Donor Age (Years)  58.20 (± 3.4)  44.7 (± 11.9)  P= 0.05  
Type of Transplant        
  LRRT  1  11    
  LURT  2  13    
  DDRT  0  1  P= 1.00  
Donor Gender        
  Male  0  7    
  Female  3  18  P= 0.55  
Donor Race        
  Caucasian  2  23    
  AA  1  0    
  Asian  0  1  P=  0.21  
Warm Ischemia Time (min)  34.00(± 9.8)  48.70 (± 
27.6)  
P= 0.68  
Cold Ischemia Time (min)  168.7(± 
243.7)  
57.10 (± 
81.2)  
P= 0.49  
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DISCUSSION 
 
 
 This thesis, as previously introduced, is a small part of a significantly 
larger study examining the adaptive immune response to BKV reactivation. The 
larger study focuses on the methodologies employed in order to measure and 
describe the multiple aspects of the immune response involved in BKV 
reactivation. The mastery, through trial and error, of the assays and techniques 
employed will no doubt further refine research questions and methods for future 
BKV research. The smaller study, however, focuses on the plasma and urine 
from 29 patients, procured pre-transplant, one month, three months, six months 
and twelve months post transplant. The viral BK DNA was extracted from each 
sample and then quantified with qPCR. This data was added to the larger 
compilation of data examining several other aspects of the adaptive immune 
response to BKV reactivation.  
 The approach used in this study is very much in line with the myriad of 
previous research publications. Extensive data regarding the kidney transplant 
patients was gathered. Apart from their demographic information that is 
presented in the following figures, details about their underlying medical 
conditions and comorbidities were factored into the study.  
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Patient Demographics 
A detailed summary of the population characteristics of this study is 
presented in Table 10. This study followed 29 patients and spanned more than 
four years. The median age of the kidney transplant recipients was 51.79 with the 
youngest and oldest patients being 26 and 70 respectively. As suggested by 
Sawinski and Goral, 2015, an older KTR age correlates to a higher risk of 
developing BKVAN.  
As Figure 10 shows, 69% of the patients in this study were male and 31% 
were female. This also reiterates the finding that male gender is an inherent risk 
for developing BK viremia and BKVAN (Hirsch, 2002).  
Figure 11, a breakdown of the race distribution of the patients in the study, 
shows that the majority of patients were White or Caucasian. There is currently 
no published data elucidating any link between race and risk for developing BK 
viremia or BKVAN. However, it is interesting to note that 80% of Caucasians 
possess the HLA-A allele 2 and are thus more likely to have a lower degree of 
HLA mismatching compared to other races.  
 
Risk Factors: Underlying medical conditions, Comorbidities, Complications 
during Transplant and degree of HLA mismatch 
All of the patients in this study had underlying medical conditions and 
other comorbidities. These factors undoubtedly affected their physicians’ planned 
course of treatment, the occurrence of complications during transplant, recovery 
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from the transplant procedure and pharmacologic immunosuppression regimen. 
Some of the underlying medical conditions include crescentic glomerulonephritis, 
calcineurin inhibitor (CNI) toxicity, Type I Diabetes (T1DM), chronic 
pyelonephritis, Type II Diabetes (T2DM), uncontrolled hypertension (HTN), 
polycystic kidney disease (PKD), IgA nephropathy and Focal Segmental 
Glomerulosclerosis (FSGS).  
Some of the comorbidities included but were not limited to obesity, gout, 
hyperlipidemia, hypertension, cystic fibrosis (CF), pancreatic insufficiency, 
hypothyroidism, coronary artery disease (CAD), MRSA (Methicillin Resistant 
Staphylococcus Aureus) infection, polymyositosis, renal cell cancer and Hepatitis 
C. Only one patient was without comorbidities. As suggested by previous 
research studies (Sawinksi & Goral, 2015), co-infection with Cytomegalovirus 
(CMV) is a risk factor for BKV reactivation post-transplant. As such, the CMV 
status of both the recipients and donors was also taken into account. 37% of the 
donors had a positive CMV status compared to only 25% of the recipients.  
As with any surgery, unexpected complications sometimes arise. During 
the transplant procedures, only 11% of KTRs experienced surgical complications. 
These included, allograft vessel complications and either urinary or wound 
infections. All patients were administered either rabbit anti-thymocyte globulin 
(rATG) or Basiliximab, a monoclonal antibody as induction of immune 
suppression in order to prevent acute rejection of the allograft. 
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Much research has focused on the degree of HLA (Human Leukocyte 
Antigen) mismatching and the correlated increased risk for developing BKVAN 
(Awadalla et al, 2004).  In this study, the donors were test for HLA-A allele 1 and 
HLA-A allele 2. It is important to note that HLA matching is not performed prior to 
the kidney transplant. This is standard protocol with kidney transplants. With 
respect to the renal allograft donors, 53.6% of donors were living and unrelated 
to the recipient, 42.9% were living and related to the recipient and 3.6% were 
Standard Criteria Deceased donors.  
 
Pharmacologic Immunosuppression  
In this study, the pharmacologic immunosuppression regimen was 
different for almost each patient. Trough levels, the lowest concentration 
detected in the body, of immunosuppressive drugs were measured at each time 
point. These immunosuppressive agents included the calcineurin inhibitor 
Tacrolimus, an mTOR inhibitor Sirolimus, Mycophenolate mofetil, the 
antimetabolite Azathioprine, Prednisone and Cyclosporine. Leflunomide was also 
used along with immunosuppression in 97.8% of patients. In contrast, antivirals 
such as Cidofovir and Ganciclovir were administered to none of the patients in 
this study.  
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qPCR Assay 
The qPCR assay employed in this study was not completed without 
incident. Inconsistent levels of amplification and poor standard curves were 
initially observed. As such, new BKVP1 primers were purchased and the assays 
were repeated. PCR is the primary method of detecting and diagnosing 
polyomavirus-associated pathologies. As such, considerable effort must be 
allocated to troubleshooting any issues in order to ensure that accuracy and 
reliability of the assay. It is thought that such discrepancies may have attributed 
to the primers for the target sequence, BKVP1, being outdated. Dumoulin and 
Hirsch, 2011, discuss similar inconsistencies they experienced during many 
years of BKV research. They conclude that such target sequences must be 
regularly updated so as to be able to detect rare sequences in the clinical routine. 
It was also postulated that random mutations in the target sequence might have 
been responsible for the inconsistencies (Dumoulin & Hirsch, 2011). 
 Upon initial analysis, the raw qPCR data appeared exactly as expected 
according to previous research on the pathogenesis of BK infection. Patients 
exhibit viuria before viremia (Hirsch, 2005). It was not surprising that no patients 
were found to be viremic (See Figure 7). As found by previous research studies, 
viremia is considered a late stage of the BK pathogenesis (Hirsch, 2005). qPCR 
analysis of the urine samples yielded that 21% of patients in the study exhibited 
BK viuria (See Figure 8). This statistic was also not unexpected. It must be noted 
	  40 
that discrepancies only arose when qPCR data from the laboratory assay was 
compared to the PCR data from the clinical assay as represented in Figure 9. 
 
Observed Inconsistencies between Lab PCR and Clinical PCR Data 
The data presented in Table 6 and Table 7 draws attention to the 
significant disparity between the results gathered from the clinical and the 
laboratory PCR assays. The clinical PCR data clearly shows that more patients 
were classified as viuric at more time points during the study. Interestingly, one 
patient who was initially classified as non-viuric according to the clinical assay 
was reclassified as viuric when the results from the laboratory assay were 
analyzed. Contamination was ruled out as the sample was run in triplicate and all 
three wells yielded a positive result. It must be noted however, that the laboratory 
and clinical plasma and urine samples were collected on different days. The 
clinical samples were collected, on average, two to eight days before the 
laboratory samples were collected. Degrees of viuria and viremia are extremely 
labile. As such, the patient’s viuria or viremia may have resolved by the time the 
biological samples was procured for laboratory analysis. 
No patients were found to be viremic compared to two patients each at the 
3-month and 6-month time-point post-transplant according to lab qPCR data 
shown in Table 7. This discrepancy may be accounted for by the fact that the 
qPCR assay used in the lab is not a valid clinical assay and as such, may be less 
sensitive than the clinical PCR assay. 
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It is extremely significant to note that this study was very small by scientific 
convention. With data only on 29 kidney transplant recipients, statistics gathered 
may easily be compromised by anomalous or particularly medically complicated 
patients. With the initiation of NEBKCON (New England BK Consortium), it is 
hoped that data from a much larger sample size may be procured and analyzed.  
 
Serology Data 	   Serology data was also analyzed as part of the larger study examining the 
immune response to BKV reactivation.  Anti BKV IgG was quantified for each 
patient at each time-point post-transplant. The analysis, as seen in Figure 10, 
shows that levels of Anti-BK IgG increased more sharply for viremic patients as 
time progressed post-transplant.    
 
Future Research Directions 
Research on BKV will no doubt lead to improved outcomes for kidney 
transplant patients with viremia or BKVAN. Having attended the inaugural 
convention of the New England BK Consortium, it is clear that clinically, a 
standard protocol for meticulous BK surveillance of kidney transplant recipients 
should be established. With a standardized set of data from an extensive number 
of academic medical centers across New England, more accurate trends may be 
observed and conclusions drawn.  
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 Experimentally, the dynamics of both the adaptive and humoral immune 
response will yield more information about the pathogenesis of BK nephropathy.  
 A review of the scientific literature on BK virus pathogenesis has yielded 
future directions for research with regards to the oncogenic nature of the BK 
polyomavirus (Hassan et al, 2013). It has been observed that consistently high 
viremic levels of BK are associated with tumor formation and malignancy such as 
adenocarcinoma of the bladder (Hassan et al, 2013). Research at the University 
of North Carolina Chapel Hill Division of Nephropathology conducted research on 
a novel strain of BK polyomavirus and concluded that viral integration into the 
human genome of kidney transplant recipients is essentially linked with 
tumourigenesis (Kenan et al, 2015). Further research into this facet of BK virus 
pathogenesis would undoubtedly help clinicians and researchers better predict 
outcomes and possible complications for renal allograft recipients with BK 
viremia and BKVAN. 
 
Conclusions 	   Disregarding the small sample size of this study, BK virus was 
successfully quantitated from renal transplant patient’s plasma and urine 
samples at pre-transplant, 1 month, 3 months, 6 months and 12 months post-
transplant. Data from both clinical and laboratory PCR assays were analyzed and 
the immune response to BK was summarized. Future research directions were 
also established. 	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